# OnCo record paper-asco-pembrolizumab-early-tnbc-rapid-update-jco-2022 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-asco-pembrolizumab-early-tnbc-rapid-update-jco-2022/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-asco-pembrolizumab-early-tnbc-rapid-update-jco-2022" ;
  schema:name "Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update"@en ;
  schema:description "The 2022 fast-track amendment in which the US oncology society added pembrolizumab before and after surgery for high-risk early triple-negative breast cancer, a year after its main guideline had said the evidence was insufficient."@en ;
  schema:url <https://onco.cc/key-papers/paper-asco-pembrolizumab-early-tnbc-rapid-update-jco-2022/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1200/JCO.22.00503>, <https://pubmed.ncbi.nlm.nih.gov/35417251/> ;
  onco:tag "tnbc-evidence" ;
  schema:sameAs <https://doi.org/10.1200/JCO.22.00503> ;
  schema:datePublished "2022"^^xsd:gYear ;
  schema:author "Korde LA, Somerfield MR, Hershman DL, et al." ;
  onco:related <https://onco.cc/key-papers/paper-asco-neoadjuvant-therapy-breast-guideline-jco-2021/> ;
  onco:cancers <https://onco.cc/cancers/tnbc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/> ;
  onco:institutions <https://onco.cc/institutions/asco/> ;
  onco:trials <https://onco.cc/trials/keynote-522/>, <https://onco.cc/trials/optimice-pcr/> ;
  onco:journals <https://onco.cc/journals/jco/> .